Another 89Zr‐labeled onartuzumab (c‐Met antibody) was studied for its application as PET probe for discriminating the fluctuation in c‐Met expression induced by erlotinib (tyrosine kinase inhibitor) and luminespib (heat shock protein‐90, Hps90 inhibitor) in human NSCLC xenografts by Pool et al.19These experiments delineate the possibility of in vivo imaging of c‐Met receptor with 89Zr‐onartuzumab by detecting the protein upregulation due to erlotinib induced resistance, as well as downregulation of the receptor followed by HSP90‐directed therapy in human NSCLC xenograft‐bearing mice. This evidence concerns the gene MET and non-small cell lung carcinoma.